$VOR

Vor Biopharma Inc. (VOR): Submission of Matters to a Vote of Security Holders

Vor Biopharma Inc. (VOR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 vor-ex10_1.htm EX-10.1 EX-10.1 321452236 v8 Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan Adopted by the Board of Directors: April 16, 2026 Approved by the Stockholders: June 11, 2026 321452236 v8 Table of Contents Page 1. General. 1 2. Shares Subje

Original reporting
Published Jun 12, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$VOR
Neutral
medium confidence
Mentioned
$VOR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VORNeutralLow
01

Why it matters

The key new information is stockholder approval of the amended plan, which governs future equity awards and share reserve capacity; the provided excerpt does not include any new clinical or financial guidance.

02

Market read

Primarily affects equity-compensation/dilution expectations rather than near-term business performance.

03

What to watch

Traders may focus on the plan’s share reserve mechanics (initial cap plus recurring increases) when assessing longer-term dilution, even if near-term fundamentals are unchanged.

Relevance 6/10Novelty 4/10Timing: Filed June 12, 2026 (8-K) after stockholder approval on June 11, 2026

Background

The 8-K Item 5.07 reports matters submitted to a vote of security holders, including approval of an amended and restated equity incentive plan.

Company-level read

Ticker impact

$VORNeutralMedium confidence
Context

Vor Biopharma filed an 8-K disclosing stockholder approval of an amended and restated 2021 Equity Incentive Plan (approved June 11, 2026).

Expected impact

Likely limited/short-lived impact; any reaction would be more about dilution optics than new business fundamentals.

Evidence & confidence

The filing is a corporate governance/compensation plan update with no new clinical, financial, or deal terms disclosed in the provided text.

Market effects

Routine equity incentive plan updates are common in biotech; no sector-wide signal is provided here.

None indicated.

None indicated.

Counterpoint

If the plan includes an automatic annual share reserve increase (4% for 10 years), the market could re-rate dilution risk more than expected even without operating news.

Key entities

  • Vor Biopharma Inc.

    Company filing the 8-K and whose stockholders approved the amended and restated equity incentive plan.

  • Amended and Restated 2021 Equity Incentive Plan

    Equity compensation plan approved by stockholders on June 11, 2026; includes a share reserve and annual increase mechanics described in the exhibit.

Related articles

$VORHighAI 8/10

Stifel reiterates Vor Biopharma stock rating on trial milestone

Stifel reiterated a Buy rating and $40 price target for Vor Biopharma (VOR) after its earnings update, citing Phase 3 trial enrollment completion. The stock trades at $19.68, with a Strong Buy consensus and targets ranging from $27 to $50. Stifel expects top-line data in 2027 and sees potential in telitacicept for treating autoimmune diseases. The stock has surged 42% in six months and 50% year-to-date, but is above fair value according to InvestingPro.

$VORHighAI 8/10

Vor Bio Down on Q3 Results

Vor Bio (VOR) reported Q3 2026 results, with a net loss of $86.7M, down from $812.7M in Q3 2025. The company noted full enrollment in the UPSTREAM MG trial and progress in other clinical trials. CEO Jean-Paul Kress highlighted positive Phase 3 TELIGAN results for telitacicept in IgAN, showing kidney function preservation and proteinuria reduction.

$VORMed

Vor Biopharma 3Q 2026: Net loss $86.7M, EPS $(1.45) — 10-Q Summary

Vor Biopharma reported a net loss of $86.7M in 3Q 2026, narrower than the $812.7M loss a year earlier, with no revenue in either period. The company completed enrollment in the UPSTREAM MG trial and plans to start Phase 3 trials for ocular myasthenia gravis and Sjogren's disease in 2027. R&D spending increased for telitacicept programs while declining for legacy programs.

$VORHighAI 9/10

Vor Bio reports positive two-year IgA nephropathy trial data

Vor Bio (VOR) reported final results from a Phase 3 trial of telitacicept in adults with IgA nephropathy. The trial met its primary endpoint, showing a significant improvement in kidney function compared to placebo. Telitacicept reduced the risk of kidney function decline and proteinuria. Adverse events were more frequent with telitacicept but serious events were less common. Vor Bio holds exclusive rights outside China.

$VORMedAI 8/10

Vor Completes Enrollment of Global Phase 3 Upstream Mg Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

Vor Bio completed enrollment in its Phase 3 UPSTREAM MG trial for telitacicept, a treatment for generalized myasthenia gravis, with results expected in early 2027. The company plans to start a Phase 3 trial for ocular myasthenia gravis in the same timeframe, expanding its telitacicept franchise. The trials follow positive results from RemeGen's Phase 3 trial in China.